Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma...
14 KB (1,147 words) - 07:33, 11 August 2024
with polyangiitis. Patients taking mepolizumab experienced a "significant improvement" in their symptoms. Mepolizumab is a monoclonal antibody that targets...
30 KB (2,813 words) - 01:10, 1 October 2024
glucocorticoids such as prednisone. The addition of the monoclonal antibody mepolizumab may reduce the dose of glucocorticoids. Depending on eosinophil target-organ...
26 KB (2,491 words) - 20:07, 10 September 2024
eosinophils in blood are rapidly reduced monoclonal antibody therapy – e.g., mepolizumab or reslizumab against IL-5, prevents eosinophilopoiesis, or benralizumab...
29 KB (3,166 words) - 00:19, 9 September 2024
Antibodies that aid in asthma symptomatic control include omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab. Omalizumab binds...
27 KB (2,763 words) - 19:15, 18 October 2024
diets to avoid food allergies, azathioprine and antibodies, including mepolizumab, omalizumab, infliximab, and adalimumab. The word enteritis (/ˌɛntəˈraɪtɪs/)...
19 KB (1,905 words) - 04:24, 18 October 2024
in order to alleviate symptoms. Some examples of these drugs include mepolizumab, reslizumab, and benralizumab. Although eosinopenia has long been recognized...
14 KB (1,549 words) - 14:59, 25 October 2024
(naratriptan hydrochloride) Nimbex (cisatracurium besilate) Nucala (mepolizumab) Ojjaara (momelotinib) Otosporin ear drops (polymyxin B sulphate, neomycin...
7 KB (628 words) - 18:58, 27 December 2023
market in recent years have been used to treat AERD including dupilumab, mepolizumab, omalizumab, and benralizumab. Among treatment options, biologics have...
50 KB (5,530 words) - 02:09, 6 June 2024
options with oral corticosteroids, biological treatments (e.g. omalizumab, mepolizumab) or allergen immunotherapy. Eczema Asthma Rhinitis Anaphylaxis Allergic...
24 KB (2,561 words) - 17:54, 7 July 2024
helminthic therapy; a drug to suppress toll-like receptor 9 (TLR9); and mepolizumab to treat eosinophilic esophagitis. Penicillin desensitization Castells...
3 KB (406 words) - 03:39, 16 August 2024
beyond one year are unknown. Monoclonal antibody injections such as mepolizumab, dupilumab, or omalizumab may be useful in those with poorly controlled...
167 KB (18,027 words) - 23:55, 18 October 2024
there are two FDA-approved monoclonal antibodies that inhibit IL-5, mepolizumab and reslizumab. Additionally, the antibody benralizumab blocks the interleukin-5...
13 KB (1,523 words) - 19:27, 26 June 2024
mepiroxol (INN) mepitiostane (INN) mepivacaine (INN) mepixanox (INN) mepolizumab (INN) mepramidil (INN) meprednisone (INN) Mepriam Mepro-Aspirin meprobamate...
5 KB (276 words) - 15:41, 20 March 2022
inflammatory phenotype and the eosinophilic inflammatory phenotype. Mepolizumab, a monoclonal antibody, has been shown to have benefit in treating the...
159 KB (17,210 words) - 07:07, 19 October 2024
Sirukumab Spesolimab Tildrakizumab Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12...
7 KB (299 words) - 13:45, 27 April 2024
blockers: Altrakincept Pascolizumab IL-5-specific blockers: Benralizumab Mepolizumab Reslizumab IL-13-specific blockers: Lebrikizumab Tralokinumab Dual IL-4...
5 KB (560 words) - 00:25, 17 July 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
22 KB (1,812 words) - 09:08, 9 October 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
38 KB (3,075 words) - 05:52, 21 October 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
49 KB (6,005 words) - 13:33, 14 October 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
12 KB (1,289 words) - 19:20, 4 December 2023
eosinophilic granulomatosis with polyangiitis can be successfully treated with mepolizumab. Idiopathic hypereosinophilic syndrome and lymphocyte-variant hypereosinophilia:...
32 KB (3,610 words) - 06:12, 8 September 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
17 KB (1,245 words) - 14:04, 2 September 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
24 KB (2,084 words) - 05:31, 21 October 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
16 KB (1,451 words) - 18:24, 2 August 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
12 KB (1,323 words) - 14:55, 7 September 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
15 KB (1,089 words) - 18:39, 16 October 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
19 KB (2,293 words) - 11:05, 8 March 2024
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin...
43 KB (5,000 words) - 12:13, 15 September 2024
Epidermal growth factor receptor (EGFR) colorectal, lung and stomach cancer Mepolizumab Bosatria mab humanized IL-5 Y asthma and white blood cell diseases Metelimumab...
137 KB (4,083 words) - 21:25, 19 October 2024